TRX2 (trichos=hair in ancient greek; 2=second generation) is one of the world’s leading research projects exclusively devoted to providing a new standard of care for the treatment of Androgenetic Alopecia (AGA). The project has been made possible through Oxford BioLabs Ltd. and former scientists from the University of Oxford, UK. TRX2 follows several independent research paths including:
1) Hair growth
2) The prevention of hair loss
3) A cure against Androgentic Alopecia and other hair growth disorders
For our ongoing and past research projects please visit our Research page.
Mission & Goal
Our mission is to create an extraordinary customer experience by tackling Androgenetic Alopecia (AGA) through high-performance, cutting-edge science that delivers noticeable, honest results. Our goal is to create the new standard of care for the treatment of AGA.
TRX2 is run by Oxford BioLabs. The company was founded in August 2008 by former scientists from the University of Oxford and is incorporated as a Limited Liability Company in England & Wales. Oxford is one of the world’s leading centers for biochemical research and the commercialization of new technologies.
We are a team of scientists and medical authorities brought together by a shared aspiration: to challenge the status quo and end the frustrations of people suffering from hair loss. Our team consists of a growing number of
- World leading scientists in the field of potassium channel research
- Dermatologists and experts in the field of androgentic alopecia
- Medical professionals and surgeons
Scientific Lead: Dr. Thomas F.A. Whitfield DPhil
Dr. Whitfield has been an academic visitor at the University of Oxford’s Department of Biochemistry and is an internationally recognized expert in potassium channel research and the molecular mechanism of Androgenetic Alopecia. He is author of multiple peer-reviewed publications and international patents in the field of potassium channel research and Androgenetic Alopecia. Dr. Whitfield holds a DPhil in Biochemistry from the University of Oxford.
TRX2 takes advantage of the latest scientific knowledge of the molecular mechanism behind male and female pattern hair loss. The chronic blockage of potassium channels in hair follicles is a cause of hair loss.
Oxford BioLabs Ltd. received a grant award in 2009 from the National Council for Graduate Entrepreneurship (NGCE) Flying Start Entrepreneur fund. This fund was supported by the National Endowment for Science, Technology and the Arts (NESTA). For more information about NGCE and NESTA see below:
NCGE – National Council For Graduate Entrepreneurship
The NCGE is a council group based on Birmingham, UK whose purpose is to develop and promote a culture of entrepreneurship through research, education and facilitation.
Read more about NCGE
NESTA – the UK’s leading independent expert on innovation
NESTA works with public, private and third-sector partners bringing together powerful combinations of people, resources and bright ideas. NESTA combines capital investment with non-financial support to help the UK’s innovative early-stage companies turn their ideas into commercial success.
Read more about NESTA